{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:28:51Z","timestamp":1776601731982,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.vaccine.2017.02.030","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T05:01:52Z","timestamp":1488517312000},"page":"1758-1763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo\u00ae) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010\u20132015"],"prefix":"10.1016","volume":"35","author":[{"given":"Tanya R.","family":"Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.02.030_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6429a3","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2014","volume":"64","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0015","first-page":"273","article-title":"Licensure of meningococcal conjugate vaccine (Menveo) and guidance for use \u2013 Advisory Committee on Immunization Practices (ACIP), 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0020","first-page":"1018","article-title":"Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease \u2013 Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0025","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices","volume":"63","author":"Centers for Disease Control and Prevention","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0030","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W, and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in health infants","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.02.030_b0040","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2012.03.080","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in health toddlers","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0045","unstructured":"U.S. Food and Drug Administration. Package insert \u2013 Menveo\u00ae, http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM201349.pdf; 2013 [accessed 26.7.2016]."},{"key":"10.1016\/j.vaccine.2017.02.030_b0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":"Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0055","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.02.030_b0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.15585\/mmwr.mm6506a4","article-title":"Notes from the field: administration error involving a meningococcal conjugate vaccine \u2013 United States, March 1, 2010 \u2013 September 22, 2015","volume":"65","author":"Su","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.02.030_b0070","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0075","unstructured":"U.S. Code of Federal Regulations, 21 CFR 600.80. Postmarketing reporting of adverse experiences; 2014. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=600.80 [accessed 12.12.2016]."},{"key":"10.1016\/j.vaccine.2017.02.030_b0080","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.05.023","article-title":"Facial nerve palsy including Bell\u2019s palsy: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","author":"Rath","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0090","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.02.030_b0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2017.02.030_b0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2017.02.030_b0105","first-page":"457","article-title":"Syncope after vaccination \u2013 United States, January 2005\u2013July 2007","volume":"57","author":"Sutherland","year":"2008","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2017.02.030_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40264-016-0456-3","article-title":"Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase","volume":"40","author":"Chandler","year":"2017","journal-title":"Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17302244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T20:04:41Z","timestamp":1719086681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17302244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0264410X17302244"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo\u00ae) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010\u20132015","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}